T. Rowe Price Associates’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-30,444
| Closed | -$36.3M | – | 2523 |
|
|
2019
Q2 | $36.3M | Sell |
30,444
-3,798
| -11% | -$4.53M | 0.01% | 986 |
|
|
2019
Q1 | $42.7M | Sell |
34,242
-384
| -1% | -$478K | 0.01% | 932 |
|
|
2018
Q4 | $32.8M | Buy |
34,626
+190
| +0.6% | +$180K | 0.01% | 975 |
|
|
2018
Q3 | $49.6M | Sell |
34,436
-39
| -0.1% | -$56.2K | 0.01% | 915 |
|
|
2018
Q2 | $55.6M | Buy |
34,475
+5,767
| +20% | +$9.3M | 0.01% | 853 |
|
|
2018
Q1 | $46.6M | Buy |
28,708
+16,058
| +127% | +$26.1M | 0.01% | 901 |
|
|
2017
Q4 | $21.2M | Buy |
12,650
+1,661
| +15% | +$2.79M | ﹤0.01% | 1157 |
|
|
2017
Q3 | $15.4M | Sell |
10,989
-2,639
| -19% | -$3.69M | ﹤0.01% | 1247 |
|
|
2017
Q2 | $15.2M | Buy |
+13,628
| New | +$15.2M | ﹤0.01% | 1239 |
|
|
2015
Q1 | – | Sell |
-913
| Closed | -$658K | – | 2553 |
|
|
2014
Q4 | $658K | Buy |
+913
| New | +$658K | ﹤0.01% | 1844 |
|